Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis
- PMID: 28992224
- DOI: 10.1093/ndt/gfx206
Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis
Abstract
Background: High mortality of haemodialysis patients is associated with systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS). Insufficient elimination of pro-inflammatory immune mediators, especially in the molecular weight range of 15-45 kDa, may be one of the reasons for this. Employment of haemodialysis membranes with increased permeability was shown to ameliorate the inflammatory response and might modulate the effects of local RAS. In this study, we tested the impact of high cut-off (HCO), medium cut-off (MCO) and high-flux (HF) dialysis on leucocytic transcripts of angiotensin-converting enzymes (ACE and ACE2). Additionally, the impact of HCO, MCO and HF sera and dialysates on local ACEs and inflammation markers was tested in THP-1 monocytes.
Methods: Patients' leucocytes were obtained from our recent clinical studies comparing HCO and MCO dialysers with HF. The cells were subjected to quantitaive polymerase chain reaction (qPCR) analyses with TaqMan probes specific for ACE, ACE2 and angiotensin II (AngII) and Ang1-7 receptors. Sera and dialysates from the clinical trials as well as samples from in vitro dialysis were tested on THP-1 monocytic cells. The cells were subjected to qPCR analyses with TaqMan probes specific for ACE, ACE2, interleukin-6 and tumour necrosis factor α and immunocytochemistry with ACE and ACE2 antibodies.
Results: Leucocytes obtained from patients treated with HCO or MCO demonstrated decreased transcript expression of ACE, while ACE2 was significantly upregulated as compared with HF. Receptors for AngII and Ang1-7 remained unchanged. THP-1 monocytes preconditioned with HCO and MCO patients' or in vitro dialysis sera reflected the same expressional regulation of ACE and ACE2 as those observed in HCO and MCO leucocytes. As a complementary finding, treatment with HCO and MCO in vitro dialysates induced a pro-inflammatory response of the cells as demonstrated by elevated messenger RNA expression of tumour necrosis factor α and interleukin-6, as well as upregulation of ACE and decreased levels of ACE2.
Conclusions: Taken together, these data demonstrate that employment of membranes with high permeability eliminates a spectrum of mediators from circulation that affect the RAS components in leucocytes, especially ACE/ACE2.
Keywords: CKD; angiotensin-converting enzymes; chronic renal insufficiency; high-permeability haemodialysis; monocytes.
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Similar articles
-
Circulating miR-421 Targeting Leucocytic Angiotensin Converting Enzyme 2 Is Elevated in Patients with Chronic Kidney Disease.Nephron. 2019;141(1):61-74. doi: 10.1159/000493805. Epub 2018 Oct 16. Nephron. 2019. PMID: 30326474
-
Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease.Nephrol Dial Transplant. 2017 Feb 1;32(2):287-298. doi: 10.1093/ndt/gfw206. Nephrol Dial Transplant. 2017. PMID: 28186543 Free PMC article.
-
Impact of serum and dialysates obtained from chronic hemodialysis patients maintained on high cut-off membranes on inflammation profile in human THP-1 monocytes.Hemodial Int. 2017 Jul;21(3):348-358. doi: 10.1111/hdi.12494. Epub 2016 Sep 26. Hemodial Int. 2017. PMID: 27670395 Clinical Trial.
-
Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis.Hypertens Res. 2009 Jul;32(7):533-6. doi: 10.1038/hr.2009.74. Epub 2009 May 22. Hypertens Res. 2009. PMID: 19461648 Free PMC article. Review.
-
ACE and ACE2 in inflammation: a tale of two enzymes.Inflamm Allergy Drug Targets. 2014;13(4):224-34. doi: 10.2174/1871528113666140713164506. Inflamm Allergy Drug Targets. 2014. PMID: 25019157 Review.
Cited by
-
Expanded hemodialysis: what's up, Doc?Clin Kidney J. 2023 Feb 20;16(7):1071-1080. doi: 10.1093/ckj/sfad033. eCollection 2023 Jul. Clin Kidney J. 2023. PMID: 37398691 Free PMC article. Review.
-
Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.Front Cardiovasc Med. 2020 Dec 4;7:568720. doi: 10.3389/fcvm.2020.568720. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 33344513 Free PMC article.
-
Valvular calcification in chronic kidney disease: new insights from recent clinical and preclinical studies.Clin Kidney J. 2025 Mar 13;18(Suppl 1):i27-i45. doi: 10.1093/ckj/sfae421. eCollection 2025 Mar. Clin Kidney J. 2025. PMID: 40083956 Free PMC article.
-
Reduction in ACE2 expression in peripheral blood mononuclear cells during COVID-19 - implications for post COVID-19 conditions.BMC Infect Dis. 2024 Jul 3;24(1):663. doi: 10.1186/s12879-024-09321-0. BMC Infect Dis. 2024. PMID: 38956476 Free PMC article.
-
Exploring the Clinical Relevance of Providing Increased Removal of Large Middle Molecules.Clin J Am Soc Nephrol. 2018 May 7;13(5):805-814. doi: 10.2215/CJN.10110917. Epub 2018 Mar 5. Clin J Am Soc Nephrol. 2018. PMID: 29507008 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous